Health Professional Radio - Podcast

Rich Daly, Chief Operating Officer at Beyond Spring Inc., a biopharmaceutical company, discusses Plinabulin, the company's lead asset currently in late-stage development for the treatment of non-small cell lung cancer and the prevention of neutropenia, a common and often severe side effect of chemotherapy that can cause patients to delay, downgrade, decrease or even discontinue their dose.